Clinical Trial Services Market
完整報告名稱與涵蓋範圍
Clinical Trial Services Market by Type (Lab, Monitoring, Contracts, Recruitment, PV, Biostatistics), Phase (I, II, III), Therapy (Oncology, Neurology, Dermatology, CVD), Modality (Biologics, Devices), Delivery Model (FSP, Hybrid) - Global forecast to 2031
報告摘要
The clinical trial services market is projected to reach USD 97.41 billion by 2031 from USD 66.20 billion in 2026, at a CAGR of 8.0% during the forecast period of 2026 to 2031. The expanding pipeline of cell & gene therapies (CGTs) and precision medicines is increasing demand for specialized outsourced Phase I–IV clinical trial services. These programs often involve complex protocols, biomarker- or genomic-based patient selection, small and geographically dispersed patient populations, specialized site requirements, stringent sample handling, customized clinical supply and logistics, and extended safety follow-up. Such requirements are encouraging sponsors to engage CROs and specialized providers with capabilities in site identification and management, patient recruitment, clinical monitoring, laboratory and biomarker testing, data management, pharmacovigilance, and clinical trial logistics.
By service type, the laboratory services segment accounted for the second-largest share of the clinical trial services market in 2025.
By service type, the clinical trial services market is segmented into laboratory services, site management and monitoring, site contracts and payments, patient recruitment and retention, medical writing, clinical trial supply & logistics services, safety and pharmacovigilance, clinical trial data management services, consulting, and other clinical trial services. In 2025, laboratory services accounted for the second-largest share of the market, following site management and monitoring. The significant share of laboratory services stems from the extensive need for analytical and bioanalytical testing during Phase I–IV clinical trials to measure drug concentrations, evaluate pharmacokinetics, assess biomarkers and immunogenicity, and generate reliable laboratory data for efficacy and safety assessments. Increasing development of biologics, oncology therapies, cell & gene therapies, and other complex modalities is further increasing demand for specialized assays, biomarker testing, and high-quality bioanalytical capabilities, encouraging sponsors to outsource these activities to CROs and specialized laboratories.
By end user, the pharmaceutical & biopharmaceutical companies accounted for the largest share in the clinical trial services market in 2025.
Based on end user/sponsor, the clinical trial services market is segmented into pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes. Pharmaceutical & biopharmaceutical companies are further segmented into large and mid-size and small companies. In 2025, pharmaceutical & biopharmaceutical companies accounted for the largest market share. This segment's large share is driven by extensive Phase I–IV clinical development pipelines, substantial R&D expenditure, increasing protocol complexity, and growing reliance on CROs for global trial execution. Outsourcing enables these sponsors to access specialized therapeutic expertise, global site and patient networks, scalable clinical operations resources, and capabilities in site management and monitoring, laboratory testing, data management, pharmacovigilance, patient recruitment, and clinical trial logistics while improving operational flexibility and development efficiency.
By region, North America accounted for the largest share of the market in 2025.
In 2025, North America held the largest share of the global clinical trial services market, supported by a well-established pharmaceutical and biopharmaceutical industry, high R&D expenditure, and substantial demand for outsourced Phase I–IV clinical trial services. The region also benefits from a dense network of clinical research sites, hospitals, academic medical centers, and specialized laboratories, providing strong infrastructure for large-scale and complex clinical studies. In addition, the rapid adoption of decentralized and hybrid trial models, digital patient-engagement tools, risk-based monitoring, and advanced clinical data technologies, particularly in the US, is further supporting demand for services such as site management and monitoring, patient recruitment and retention, data management, pharmacovigilance, laboratory testing, and clinical trial logistics. These factors continue to strengthen North America’s position as the leading regional market for outsourced clinical trial services.
• List of Companies Profiled in the Report:
• IQVIA Inc. (US)
• Thermo Fisher Scientific Inc. (US)
• Fortrea (US)
• ICON Plc (Ireland)
• Syneos Health (US)
• Laboratory Corporation of America Holdings (US)
• Medpace (US)
• Wuxi AppTec (China)
• Frontage Labs (US)
• Pharmaron (US)
• Tigermed (China)
• SGS Société Générale de Surveillance SA. (Switzerland)
• Eurofins Scientific (Luxembourg)
• Linical (Japan)
• Parexel International Corporation (US)
• Worldwide Clinical Trials (US)
• Novotech (Australia)
• PSI (Switzerland)
• Allucent (US)
• Premier Research (US)
• Clario (US)
• KCR S.A. (US)
• Rho, Inc. (US)
• Advanced Clinical (US)
Research Coverage
This research report categorizes the clinical trial services market by service type, phase, therapeutic area, modality, delivery model, study design, end user/sponsor, and region.
The report provides detailed information on the key drivers, opportunities, and challenges influencing the growth of the clinical trial services market, including increasing pipeline and trial complexity, growing R&D investment, service flexibility offered by CROs, demand for faster drug-development timelines, evolving outsourcing models, regulatory modernization, AI and data analytics, decentralized and patient/site-centric trials, patient recruitment and retention challenges, and shortages of specialized clinical research talent. It also analyzes industry trends, technology developments, regulatory and sustainability considerations, customer landscape, pricing, ecosystem dynamics, and the competitive landscape. A detailed assessment of key market participants covers their service portfolios, strategies, market positioning, partnerships, agreements, and other strategic developments, including service launches, deals, collaborations, partnerships, and acquisitions associated with the clinical trial services market.
Key Benefits of Buying the Report
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall clinical trial services market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their business and develop suitable go-to-market strategies. This report will help stakeholders understand the market's pulse and provide information on key market drivers, opportunities, and challenges.
The report provides insights into the following pointers:
• Analysis of key drivers (growing pipeline complexity and increasing clinical-trial activity in specialty therapies, growing R&D investments and presence of a robust clinical pipeline, service flexibility offered by CROs, demand for faster drug-development timelines and productivity improvement, and the gradual shift from full-service CRO toward FSP/hybrid/strategic outsourcing models), opportunities (regulatory modernization and innovative trial designs, AI, automation and data analytics in clinical development, and patient/site-centric and decentralized clinical trials), and challenges (patient recruitment and retention and shortage of qualified clinical research talent and specialized expertise) influencing the growth of the clinical trial services market
• Service Development/Innovation: Detailed insights into newly introduced and evolving clinical trial services and technology-enabled solutions
• Market Development: Comprehensive information about lucrative markets—the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the clinical trial services market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, service offerings, and competitive positioning of key clinical trial service providers, including Thermo Fisher Scientific Inc. (PPD, Inc.), IQVIA Inc., ICON plc, Laboratory Corporation of America Holdings, Syneos Health, WuXi AppTec, Eurofins Scientific, Parexel International Corporation, Fortrea Inc., Medpace, SGS, Frontage Labs, Pharmaron, Tigermed, and BioAgile, among others. The report analyzes key strategies, service launches, deals, acquisitions, partnerships, agreements, collaborations, expansions, investment and funding activities, brand/service comparative analysis, and vendor valuation and financial metrics in the clinical trial services market.
授權報價
| Single User Licence | $4,950 USD |
| Multi User Licence | $6,650 USD |
| Corporate User Licence | $8,150 USD |
| Global User Licence | $10,000 USD |
目錄 Table of Contents
1 INTRODUCTION 55
1.1 STUDY OBJECTIVES 55
1.2 MARKET DEFINITION 56
1.2.1 INCLUSIONS & EXCLUSIONS 56
1.3 MARKET SCOPE 58
1.3.1 MARKETS COVERED 58
1.3.2 REGIONAL SCOPE 59
1.3.3 YEARS CONSIDERED 59
1.4 CURRENCY 59
1.5 STAKEHOLDERS 60
1.6 SUMMARY OF CHANGES 60
2 EXECUTIVE SUMMARY 62
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 62
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 64
2.3 DISRUPTIVE TRENDS SHAPING MARKET 65
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 66
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 67
3 PREMIUM INSIGHTS 69
3.1 GLOBAL CLINICAL TRIAL SERVICES MARKET SNAPSHOT 69
3.2 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY AND COUNTRY, 2025 70
3.3 CLINICAL TRIAL SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 71
4 MARKET OVERVIEW 72
4.1 INTRODUCTION 72
4.2 MARKET DYNAMICS 72
4.2.1 DRIVERS 73
4.2.1.1 Growing pipeline complexity and increasing clinical-trial activity in specialty and advanced therapies 73
4.2.1.2 Resilient biopharma R&D investment and broad clinical-development pipeline 74
4.2.1.3 Flexible and scalable service delivery offered by CROs 75
4.2.1.4 Pressure to shorten development timelines and improve clinical R&D productivity 75
4.2.1.5 Growing adoption of FSP, hybrid, and strategic portfolio-based outsourcing models 76
4.2.2 OPPORTUNITIES 76
4.2.2.1 Regulatory modernization and adoption of innovative trial designs 76
4.2.2.2 AI, automation, and advanced data analytics across clinical development 76
4.2.2.3 Patient- and site-centric, decentralized, and hybrid clinical-trial models 77
4.2.3 CHALLENGES 77
4.2.3.1 Patient recruitment, enrollment, and retention constraints 77
4.2.3.2 Shortage of qualified clinical-research talent and specialized domain expertise 77
4.3 UNMET NEEDS AND WHITE SPACES 78
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 78
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 79
5 INDUSTRY TRENDS 80
5.1 MARKET TRENDS 80
5.1.1 INTEGRATION OF HEOR AND RWE INTO CLINICAL TRIAL DESIGN 80
5.1.2 INCREASING FOCUS ON IN SILICO TRIALS 80
5.1.3 FSP AND HYBRID OUTSOURCING ARE GAINING STRATEGIC IMPORTANCE VERSUS ONE-SIZE-FITS-ALL FULL-SERVICE OUTSOURCING 81
5.1.4 SUSTAINABILITY AND ESG PRESSURES ARE SHAPING CLINICAL TRIALS 81
5.1.5 SUPPLIER CONSOLIDATION AND STRATEGIC PARTNERSHIPS REDEFINE MARKET 81
5.2 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 82
5.3 PRICING ANALYSIS 82
5.3.1 INDICATIVE PRICING RANGE, BY SERVICE TYPE, 2025 82
5.3.2 INDICATIVE PRICING ANALYSIS, BY PHASE, 2025 83
5.3.3 INDICATIVE PRICING ANALYSIS, BY REGION, 2025 84
5.4 VALUE CHAIN ANALYSIS 85
5.5 ECOSYSTEM ANALYSIS 87
5.6 INVESTMENT/FUNDING ACTIVITY 88
5.7 KEY CONFERENCES & EVENTS 89
5.8 PORTER’S FIVE FORCES ANALYSIS 90
5.8.1 THREAT OF NEW ENTRANTS 91
5.8.2 THREAT OF SUBSTITUTES 91
5.8.3 BARGAINING POWER OF BUYERS 91
5.8.4 BARGAINING POWER OF SUPPLIERS 91
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 92
5.9 IMPACT OF 2025 TRUMP TARIFF ON CLINICAL TRIAL SERVICES MARKET 92
5.9.1 INTRODUCTION 92
5.9.2 KEY TARIFF RATES 92
5.9.3 PRICE IMPACT ANALYSIS 92
5.9.4 IMPACT ON COUNTRY/REGION 93
5.9.4.1 North America 93
5.9.4.1.1 US 93
5.9.4.2 Europe 93
5.9.4.3 Asia Pacific 94
5.9.5 IMPACT ON END-USE INDUSTRIES 94
5.9.5.1 Pharmaceutical & biotech companies 94
5.9.5.2 Medical devices companies 94
5.9.5.3 Academic institutes 95
5.10 MACROECONOMIC OUTLOOK 95
5.10.1 INTRODUCTION 95
5.10.2 GDP TRENDS AND FORECAST 95
5.10.3 TRENDS IN GLOBAL CLINICAL TRIAL SERVICES MARKET 96
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVE N IMPACT, INNOVATIONS AND FUTURE APPLICATIONS 97
6.1 TECHNOLOGY ANALYSIS 97
6.1.1 KEY TECHNOLOGIES 97
6.1.1.1 AI-integrated Clinical Trial Management System (CTMS) & Electronic Trial Master File (eTMF) platforms 97
6.1.1.2 Randomization and Trial Supply Management (RTSM) 97
6.1.1.3 Electronic Data Capture (EDC) System 98
6.1.2 COMPLEMENTARY TECHNOLOGIES 99
6.1.2.1 Digital Biomarkers, Wearables & Electronic Patient-Reported Outcome (EPRO) Tools 99
6.1.2.2 Model-Informed Drug Development (MIDD) 99
6.1.2.3 Data Management and Informatics Technologies 99
6.1.2.4 Real-world evidence (RWE) & real-world data (RWD) platforms 100
6.1.3 ADJACENT TECHNOLOGY 100
6.1.3.1 Clinical trial simulation tools 100
6.2 IMPACT OF AI/GEN AI ON CLINICAL TRIAL SERVICES MARKET 101
6.2.1 INTRODUCTION 101
6.2.2 MARKET POTENTIAL ACROSS DRUG DEVELOPMENT STAGES 101
6.2.3 KEY COMPANIES IMPLEMENTING AI 103
6.2.4 FUTURE OF GENERATIVE AI IN DRUG DEVELOPMENT ECOSYSTEM 103
6.3 TECHNOLOGY/SERVICE ROADMAP 103
6.4 FUTURE APPLICATIONS 103
7 SUSTAINABILITY AND REGULATORY LANDSCAPE 104
7.1 REGIONAL REGULATIONS AND COMPLIANCE 104
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105
7.1.2 REGULATORY FRAMEWORK & CLINICAL TRIAL AUTHORIZATION 108
7.1.3 INDUSTRY STANDARDS 110
7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 111
7.3 CERTIFICATIONS, LABELING, & ECO-STANDARDS 112
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 113
8.1 DECISION-MAKING PROCESS 113
8.2 KEY STAKEHOLDERS AND BUYING CRITERIA 113
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 113
8.2.2 BUYING CRITERIA 114
8.3 CUSTOMER LANDSCAPE 116
8.3.1 BUDGET ALLOCATION TREND 116
8.3.2 ADOPTION BARRIER & INTERNAL CHALLENGES 116
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 117
8.5 MARKET PROFITABILITY 117
9 CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE 118
9.1 INTRODUCTION 119
9.2 CLINICAL TRIAL MANAGEMENT & MONITORING 120
9.2.1 ADOPTION OF ADVANCED TECHNOLOGIES SUCH AS ARTIFICIAL INTELLIGENCE AND RISE OF REMOTE CLINICAL MONITORING TO SUPPORT MARKET GROWTH 120
9.3 LABORATORY SERVICES 124
9.3.1 ANALYTICAL TESTING SERVICES 128
9.3.1.1 Increasing demand for analytical testing for drug development to drive market 128
9.3.2 BIOANALYTICAL TESTING SERVICES 131
9.3.2.1 Rising focus on biologics in advanced therapies to drive market 131
9.4 CLINICAL TRIAL DATA MANAGEMENT SERVICES 135
9.4.1 GROWING RELIANCE ON DATA FOR CLINICAL EVALUATIONS BY REGULATORY BODIES TO SUPPORT MARKET GROWTH 135
9.4.2 BIOSTATISTICS 140
9.4.2.1 Integration of real-world data (RWD) into statistical analysis to support market growth 140
9.4.3 OTHER DATA MANAGEMENT SERVICES 143
9.5 CLINICAL TRIAL SUPPLY & LOGISTICS SERVICES 146
9.5.1 COMPLEXITIES ASSOCIATED WITH SUPPLY AND LOGISTICS TO DRIVE MARKET 146
9.6 CONSULTING 150
9.6.1 INCREASING COMPLEXITIES DURING TRIALS TO DRIVE MARKET 150
9.7 PATIENT RECRUITMENT & RETENTION 153
9.7.1 INCREASING REQUIREMENT FOR DECENTRALIZED CLINICAL TRIAL SERVICES TO BOOST MARKET GROWTH 153
9.8 MEDICAL WRITING 156
9.8.1 INCREASED OUTSOURCING OF MEDICAL WRITING SERVICES IN EMERGING ECONOMIES TO DRIVE MARKET 156
9.9 SAFETY & PHARMACOVIGILANCE 159
9.9.1 REGULATORY AND SAFETY MONITORING EXPERTISE OFFERED BY CROS TO SUPPORT MARKET GROWTH 159
9.10 SITE CONTRACTS & PAYMENTS 163
9.10.1 GROWING NEED FOR STREAMLINED SITE CONTRACTING AND PAYMENT MANAGEMENT TO SUPPORT MARKET GROWTH 163
9.11 OTHER SERVICE TYPES 166
10 CLINICAL TRIAL SERVICES MARKET, BY PHASE 170
10.1 INTRODUCTION 171
10.2 PHASE III 172
10.2.1 HIGH SIGNIFICANCE OF PHASE III TRIALS TO DRIVE DEMAND FOR OUTSOURCING 172
10.3 PHASE II 175
10.3.1 LONG DURATION OF PHASE II STUDIES TO CREATE GROWTH OPPORTUNITIES FOR CROS 175
10.4 PHASE I 179
10.4.1 DECLINING TRIALS TO POSE GROWTH CHALLENGE TO MARKET 179
10.5 PHASE IV 182
10.5.1 SIGNIFICANCE OF PHASE IV TO SUPPORT MARKET GROWTH 182
11 CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL 185
11.1 INTRODUCTION 186
11.2 FULL-SERVICE OUTSOURCING (FSO) MODEL 186
11.2.1 RISE IN NUMBER OF EMERGING BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET 186
11.3 FUNCTIONAL SERVICE PROVIDER (FSP) MODEL 189
11.3.1 GROWING ADOPTION OF FSP SERVICES BY LARGE PHARMACEUTICAL COMPANIES TO FUEL MARKET GROWTH 189
11.4 HYBRID MODEL 192
11.4.1 HIGH FLEXIBILITY OFFERED BY HYBRID MODEL TO SUPPORT MARKET GROWTH 192
12 CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN 195
12.1 INTRODUCTION 196
12.2 INTERVENTIONAL 196
12.2.1 MAJOR ROLE OF INTERVENTIONAL TRIALS IN EVALUATING SAFETY AND EFFICACY OF NEW DRUGS AND DEVICES TO DRIVE MARKET 196
12.3 OBSERVATIONAL 200
12.3.1 INCREASING RELIANCE ON OBSERVATIONAL STUDIES TO EVALUATE EFFICACY OF DRUGS IN REAL-WORLD SCENARIO TO SUPPORT MARKET GROWTH 200
13 CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA 204
13.1 INTRODUCTION 205
13.2 ONCOLOGY 206
13.2.1 GROWING DISEASE BURDEN AND FOCUS ON DEVELOPING NOVEL MEDICINES FOR CANCER TO DRIVE MARKET 206
13.2.2 BREAST CANCER 211
13.2.2.1 Increasing cases and high spending on treating breast cancer to support growth 211
13.2.3 LUNG CANCER 215
13.2.3.1 Increasing focus on developing drugs against lung cancer to foster growth 215
13.2.4 COLORECTAL CANCER 218
13.2.4.1 Increasing drug discovery and development efforts against colorectal cancer to aid growth 218
13.2.5 PROSTATE CANCER 222
13.2.5.1 Growing clinical pipeline to propel market 222
13.2.6 OTHER CANCER 225
13.3 NEUROLOGY 228
13.3.1 INCREASING R&D INVESTMENTS RELATED TO NEUROLOGICAL DISORDERS TO DRIVE MARKET 228
13.4 RESPIRATORY DISORDERS 232
13.4.1 RISING INCIDENCE OF RESPIRATORY DISORDERS TO SUPPORT MARKET GROWTH 232
13.5 METABOLIC DISORDERS/ENDOCRINOLOGY 236
13.5.1 INCREASING GLOBAL DIABETES POPULATION TO BOOST MARKET GROWTH 236
13.6 CARDIOVASCULAR SYSTEM DISORDERS 240
13.6.1 HIGH FOCUS ON PHARMACEUTICAL R&D ATTRIBUTED TO RISING MORTALITY RATES DUE TO CVD TO DRIVE MARKET 240
13.7 DERMATOLOGY 243
13.7.1 GROWING FOCUS ON DRUG DEVELOPMENT FOR DIFFERENT SKIN CONDITIONS TO SUPPORT MARKET GROWTH 243
13.8 GASTROINTESTINAL DISEASES 247
13.8.1 EXPANSION AND DEVELOPMENT OF GASTROINTESTINAL DRUG PRODUCT LINE TO PROPEL MARKET 247
13.9 IMMUNOLOGICAL DISORDERS 250
13.9.1 GROWING CLINICAL RESEARCH FOR IMMUNOLOGICAL DISORDERS TO FUEL MARKET GROWTH 250
13.10 INFECTIOUS DISEASES 254
13.10.1 RISING OUTBREAKS OF INFECTIOUS DISEASES TO INCREASE DRUG DISCOVERY ACTIVITIES AND DRIVE MARKET 254
13.11 PSYCHIATRY 257
13.11.1 GROWING INCIDENCE OF PSYCHIATRIC DISORDERS TO SUPPORT MARKET GROWTH 257
13.12 OPHTHALMOLOGY 261
13.12.1 RISING NUMBER OF OPHTHALMOLOGY PIPELINE DRUGS TO SUPPORT SEGMENT GROWTH 261
13.13 HEMATOLOGY 265
13.13.1 CONSISTENT DRUG DEVELOPMENT EFFORTS FOR HEMATOLOGICAL DISORDERS TO SUPPORT MARKET GROWTH 265
13.14 GENITOURINARY & WOMEN’S HEALTH 268
13.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN TO PROPEL MARKET 268
13.15 OTHER THERAPEUTIC AREAS 272
14 CLINICAL TRIAL SERVICES MARKET, BY MODALITY 276
14.1 INTRODUCTION 277
14.2 SMALL MOLECULES 277
14.2.1 STRONG PIPELINE GROWTH AND GROWING INVESTMENTS TO SUPPORT GROWTH 277
14.3 BIOLOGICS 280
14.3.1 GROWING COLLABORATIONS TO DEVELOP NEW BIOLOGICS AND REGULATORY SUPPORT TO PROPEL DEMAND 280
14.4 MONOCLONAL ANTIBODY 283
14.4.1 SURGING DEMAND FOR TARGETED THERAPIES TO DRIVE MARKET 283
14.5 CELL & GENE THERAPY 286
14.5.1 DEVELOPMENT COMPLEXITY AND REGULATORY MOMENTUM TO DRIVE CRO DEMAND 286
14.6 OTHER BIOLOGICS 289
14.7 BIOSIMILARS 292
14.7.1 INCREASING DEMAND FOR COST-EFFECTIVE ALTERNATIVES TO SUPPORT BIOSIMILARS GROWTH, THUS AIDING OUTSOURCING 292
14.8 MEDICAL DEVICES & IVD 294
14.8.1 SPECIALIZED SERVICES OFFERED BY CROS TO DRIVE DEMAND 294
15 CLINICAL TRIAL SERVICES MARKET, BY END USER 298
15.1 INTRODUCTION 299
15.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 299
15.2.1 INCREASE IN R&D EXPENDITURE OF PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET 299
15.2.2 LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 303
15.2.2.1 Demand for therapeutic expertise and global reach to aid outsourcing to CROs 303
15.2.3 SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 306
15.2.3.1 Demand driven by limited internal capabilities and rising trial complexity 306
15.3 MEDICAL DEVICE COMPANIES 309
15.3.1 RISING REGULATORY EVIDENCE REQUIREMENTS AND EXPANSION OF INTEGRATED SERVICE PORTFOLIOS BY MEDTECH CROS TO DRIVE MARKET GROWTH 309
15.4 ACADEMIC INSTITUTES 313
15.4.1 EXPANDING CRO–ACADEMIC PARTNERSHIPS AND SITE NETWORKS TO DRIVE MARKET 313
16 CLINICAL TRIAL SERVICES MARKET, BY REGION 317
16.1 INTRODUCTION 318
16.2 NORTH AMERICA 318
16.2.1 US 325
16.2.1.1 Presence of well-established CROs to drive market 325
16.2.2 CANADA 331
16.2.2.1 Favorable government-led initiatives and rising R&D investments to drive market 331
16.3 EUROPE 337
16.3.1 GERMANY 343
16.3.1.1 Growing R&D spending and favorable government policies to propel market 343
16.3.2 UK 349
16.3.2.1 Rising collaborations and improved policies to support market 349
16.3.3 FRANCE 355
16.3.3.1 Government-led support for effective drug research to drive market 355
16.3.4 ITALY 361
16.3.4.1 Government-led focus on improving clinical trial regulations to drive market 361
16.3.5 SPAIN 366
16.3.5.1 Rising R&D expenditure to boost market growth 366
16.3.6 REST OF EUROPE 371
16.4 ASIA PACIFIC 377
16.4.1 CHINA 383
16.4.1.1 Low manufacturing cost and increased establishment of R&D centers to drive market 383
16.4.2 INDIA 389
16.4.2.1 Cost-efficient and innovation-driven approach to propel market 389
16.4.3 JAPAN 395
16.4.3.1 Slight decline in number of clinical trials to limit market 395
16.4.4 AUSTRALIA 400
16.4.4.1 Favorable tax incentives and cash rebates to pharmaceutical companies to support market 400
16.4.5 SOUTH KOREA 405
16.4.5.1 Favorable government initiatives for drug development to drive market 405
16.4.6 REST OF ASIA PACIFIC 411
16.5 LATIN AMERICA 416
16.5.1 BRAZIL 421
16.5.1.1 Government-led support through improved policies in pharmaceutical R&D to drive market 421
16.5.2 MEXICO 427
16.5.2.1 Increasing investments in pharma R&D to drive market 427
16.5.3 REST OF LATIN AMERICA 432
16.6 MIDDLE EAST 437
16.6.1 GCC COUNTRIES 442
16.6.1.1 Saudi Arabia 447
16.6.1.1.1 Increase in collaborations to drive market 447
16.6.1.2 UAE 452
16.6.1.2.1 Growing clinical research activities to drive market 452
16.6.1.3 Rest of GCC Countries 457
16.6.2 REST OF MIDDLE EAST 462
16.6.3 AFRICA 467
16.6.3.1 Expanding pharmaceutical industry to support market growth 467
17 COMPETITIVE LANDSCAPE 472
17.1 OVERVIEW 472
17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023–2025 472
17.3 REVENUE ANALYSIS, 2023–2025 475
17.3.1 CLINICAL TRIAL SERVICES MARKET 475
17.4 MARKET SHARE ANALYSIS, 2025 476
17.4.1 CLINICAL TRIAL SERVICES MARKET 476
17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 479
17.5.1 CLINICAL TRIAL SERVICES MARKET 479
17.5.2 STARS 479
17.5.3 EMERGING LEADERS 479
17.5.4 PERVASIVE PLAYERS 479
17.5.5 PARTICIPANTS 479
17.5.5.1 Company footprint: Key players, 2025 481
17.5.5.1.1 Company footprint 481
17.5.5.2 Region footprint 482
17.5.5.3 Service type footprint 483
17.5.5.4 Phase footprint 484
17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 485
17.6.1 CLINICAL TRIAL SERVICES MARKET: STARTUPS/SMES, 2025 485
17.6.2 PROGRESSIVE COMPANIES 485
17.6.3 RESPONSIVE COMPANIES 485
17.6.4 DYNAMIC COMPANIES 485
17.6.5 STARTING BLOCKS 485
17.6.5.1 Competitive benchmarking 487
17.6.5.1.1 Detailed list of key startups/SMES 487
17.6.5.1.2 Competitive benchmarking of startups/SMEs 488
17.7 COMPANY VALUATION AND FINANCIAL METRICS 489
17.7.1 CLINICAL TRIAL SERVICES MARKET 489
17.8 BRAND/SERVICE COMPARISON 490
17.9 COMPETITIVE SCENARIO 491
17.9.1 SERVICE LAUNCHES 491
17.9.2 DEALS 492
17.9.3 EXPANSIONS 493
18 COMPANY PROFILES 494
18.1 KEY PLAYERS 494
18.1.1 IQVIA INC. 494
18.1.1.1 Business overview 494
18.1.1.2 Solutions/Services offered 495
18.1.1.3 Recent developments 497
18.1.1.3.1 Service/Solution launches 497
18.1.1.3.2 Deals 498
18.1.1.4 MnM view 499
18.1.1.4.1 Right to win 499
18.1.1.4.2 Strategic choices 500
18.1.1.4.3 Weaknesses and competitive threats 500
18.1.2 ICON PLC 501
18.1.2.1 Business overview 501
18.1.2.2 Services/Solutions offered 502
18.1.2.3 Recent developments 504
18.1.2.3.1 Service launches 504
18.1.2.3.2 Deals 505
18.1.2.3.3 Expansions 506
18.1.2.4 MnM view 506
18.1.2.4.1 Right to win 506
18.1.2.4.2 Strategic choices 506
18.1.2.4.3 Weaknesses and competitive threats 506
18.1.3 THERMO FISHER SCIENTIFIC INC. 507
18.1.3.1 Business overview 507
18.1.3.2 Services/Solutions offered 508
18.1.3.3 Recent developments 511
18.1.3.3.1 Product/Service launches 511
18.1.3.3.2 Deals 512
18.1.3.3.3 Expansions 513
18.1.3.4 MnM view 513
18.1.3.4.1 Right to win 513
18.1.3.4.2 Strategic choices 514
18.1.3.4.3 Weaknesses and competitive threats 514
18.1.4 FORTREA 515
18.1.4.1 Business overview 515
18.1.4.2 Services/Solutions offered 516
18.1.4.3 Recent developments 519
18.1.4.3.1 Service launches 519
18.1.4.3.2 Deals 520
18.1.4.3.3 Expansions 520
18.1.4.3.4 Other developments 520
18.1.4.4 MnM view 521
18.1.4.4.1 Right to win 521
18.1.4.4.2 Strategic choices 521
18.1.4.4.3 Weaknesses and competitive threats 521
18.1.5 SYNEOS HEALTH 522
18.1.5.1 Business overview 522
18.1.5.2 Services/Solutions offered 523
18.1.5.3 Recent developments 524
18.1.5.3.1 Service launches 524
18.1.5.3.2 Deals 525
18.1.6 LABORATORY CORPORATION OF AMERICA HOLDINGS 526
18.1.6.1 Business overview 526
18.1.6.2 Services/Solutions offered 527
18.1.6.3 Recent developments 528
18.1.6.3.1 Service/ Solution launches 528
18.1.6.3.2 Deals 529
18.1.6.3.3 Expansions 530
18.1.6.4 MnM view 530
18.1.6.4.1 Right to win 530
18.1.6.4.2 Strategic choices 530
18.1.6.4.3 Weaknesses and competitive threats 530
18.1.7 MEDPACE 531
18.1.7.1 Business overview 531
18.1.7.2 Services/Solutions offered 532
18.1.8 WUXI APPTEC 534
18.1.8.1 Business overview 534
18.1.8.2 Services/Solutions offered 535
18.1.8.3 Recent developments 537
18.1.8.3.1 Deals 537
18.1.8.3.2 Expansions 537
18.1.8.4 Other developments 537
18.1.9 FRONTAGE LABS 538
18.1.9.1 Business overview 538
18.1.9.2 Services/Solutions offered 539
18.1.9.3 Recent developments 540
18.1.9.3.1 Deals 540
18.1.10 PHARMARON 541
18.1.10.1 Business overview 541
18.1.10.2 Services/Solutions offered 543
18.1.11 TIGERMED 544
18.1.11.1 Business overview 544
18.1.11.2 Services offered 545
18.1.11.3 Recent developments 547
18.1.11.3.1 Service approvals 547
18.1.11.3.2 Deals 548
18.1.12 SGS SA 549
18.1.12.1 Business overview 549
18.1.12.2 Services/Solutions offered 550
18.1.12.3 Recent developments 552
18.1.12.3.1 Deals 552
18.1.12.3.2 Expansions 552
18.1.13 EUROFINS SCIENTIFIC 553
18.1.13.1 Business overview 553
18.1.13.2 Services/Solutions offered 554
18.1.14 LINICAL 556
18.1.14.1 Business overview 556
18.1.14.2 Services/Solutions offered 557
18.1.14.3 Recent developments 558
18.1.14.4 Expansions 558
18.1.15 PAREXEL INTERNATIONAL CORPORATION 559
18.1.15.1 Business overview 559
18.1.15.2 Services/Solutions offered 559
18.1.15.3 Recent developments 561
18.1.15.3.1 Product & service launches 561
18.1.15.3.2 Deals 561
18.1.15.3.3 Expansions 562
18.1.16 PSI CRO AG 563
18.1.16.1 Business overview 563
18.1.16.2 Services/Solutions offered 563
18.1.16.3 Recent developments 564
18.1.16.3.1 Service launches 564
18.1.16.3.2 Deals 564
18.1.16.3.3 Expansions 565
18.1.17 NOVOTECH 566
18.1.17.1 Business overview 566
18.1.17.2 Services/Solutions offered 566
18.1.17.3 Recent developments 569
18.1.17.3.1 Deals 569
18.1.18 BIOAGILE 570
18.1.18.1 Business overview 570
18.1.18.2 Services/Solutions offered 570
18.1.19 ADVANCED CLINICAL 572
18.1.19.1 Business overview 572
18.1.19.2 Services/Solutions offered 572
18.1.19.3 Recent developments 573
18.1.19.3.1 Deals 573
18.1.20 FIRMA CLINICAL RESEARCH 574
18.1.20.1 Business overview 574
18.1.20.2 Services/Solutions offered 574
18.2 OTHER PLAYERS 575
18.2.1 WORLDWIDE CLINICAL TRIALS 575
18.2.2 PROPHARMA 576
18.2.3 ALLUCENT 578
18.2.4 PREMIER RESEARCH 579
18.2.5 CAIDYA 580
18.2.6 ERGOMED GROUP 581
18.2.7 CLARIO 583
18.2.8 PRECISION MEDICINE GROUP, LLC. 584
18.2.9 EPS HOLDINGS, INC. 585
18.2.10 GUIRES INC. (PEPGRA) 586
18.2.11 KCR S.A. 587
19 RESEARCH METHODOLOGY 588
19.1 RESEARCH APPROACH 588
19.1.1 SECONDARY DATA 589
19.1.1.1 Key sources of secondary data 589
19.1.1.2 Key objectives of secondary research 589
19.1.2 PRIMARY DATA 590
19.1.2.1 Breakdown of primaries 590
19.1.2.2 Key objectives of primary research 590
19.2 MARKET ESTIMATION METHODOLOGY 591
19.2.1 COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH) 591
19.2.2 MNM REPOSITORY ANALYSIS AND PRIMARY RESEARCH 593
19.2.3 SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH) 594
19.3 GROWTH RATE PROJECTIONS 595
19.4 DATA TRIANGULATION 597
19.5 RESEARCH ASSUMPTIONS 598
19.6 RESEARCH LIMITATIONS 599
19.7 RISK ANALYSIS 599
20 APPENDIX 600
20.1 DISCUSSION GUIDE 600
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 605
20.3 CUSTOMIZATION OPTIONS 607
20.4 RELATED REPORTS 607
20.5 AUTHOR DETAILS 608
圖表清單 List of Tables & Figures
TABLE 1 CLINICAL TRIAL SERVICES MARKET: IMPACT ANALYSIS 73
TABLE 2 INDICATIVE PRICING RANGE, BY SERVICE TYPE, 2025 82
TABLE 3 INDICATIVE PRICING ANALYSIS, BY PHASE, 2025 83
TABLE 4 INDICATIVE PRICING ANALYSIS (PER STUDY), BY REGION, 2025 (USD MILLION) 84
TABLE 5 CLINICAL TRIAL SERVICES MARKET: ROLE OF COMPANIES IN ECOSYSTEM 87
TABLE 6 DETAILED LIST OF KEY CONFERENCES & EVENTS, 2026–2027 89
TABLE 7 PORTER’S FIVE FORCES ANALYSIS: CLINICAL TRIAL SERVICES MARKET 90
TABLE 8 REGULATORY GUIDANCE, BY PHASE 104
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 106
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 106
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 107
TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 108
TABLE 13 CLINICAL TRIAL AUTHORIZATION SCENARIO 109
TABLE 14 COUNTRY-WISE REGULATORY SCENARIO FOR CLINICAL TRIAL SPONSORS
AND CROS 110
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CLINICAL TRIAL SERVICES, BY MODALITY 114
TABLE 16 BUYING CRITERIA FOR CLINICAL TRIAL SERVICES ACROSS END USERS 114
TABLE 17 CLINICAL TRIAL SERVICES: ADOPTION BARRIER & INTERNAL FRICTION 116
TABLE 18 CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 119
TABLE 19 CLINICAL TRIAL SERVICES MARKET FOR CLINICAL TRIAL MANAGEMENT & MONITORING, BY REGION, 2024–2031 (USD MILLION) 121
TABLE 20 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR CLINICAL TRIAL MANAGEMENT & MONITORING, BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 21 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR CLINICAL TRIAL MANAGEMENT & MONITORING, BY COUNTRY, 2024–2031 (USD MILLION) 122
TABLE 22 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR CLINICAL TRIAL MANAGEMENT & MONITORING, BY COUNTRY, 2024–2031 (USD MILLION) 122
TABLE 23 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR CLINICAL TRIAL MANAGEMENT & MONITORING, BY COUNTRY, 2024–2031 (USD MILLION) 123
TABLE 24 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR CLINICAL TRIAL MANAGEMENT & MONITORING, BY COUNTRY, 2024–2031 (USD MILLION) 123
TABLE 25 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR CLINICAL TRIAL MANAGEMENT & MONITORING, BY COUNTRY, 2024–2031 (USD MILLION) 123
TABLE 26 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS 124
TABLE 27 CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY REGION, 2024–2031 (USD MILLION) 125
TABLE 28 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 125
TABLE 29 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 126
TABLE 30 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 126
TABLE 31 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 32 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,
BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 33 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 34 CLINICAL TRIAL SERVICES MARKET FOR ANALYTICAL TESTING SERVICES,
BY REGION, 2024–2031 (USD MILLION) 128
TABLE 35 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR ANALYTICAL TESTING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 36 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR ANALYTICAL TESTING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 37 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR ANALYTICAL TESTING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 38 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR ANALYTICAL TESTING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 39 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR ANALYTICAL TESTING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 40 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR ANALYTICAL TESTING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 41 CLINICAL TRIAL SERVICES MARKET FOR BIOANALYTICAL TESTING SERVICES,
BY REGION, 2024–2031 (USD MILLION) 132
TABLE 42 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOANALYTICAL TESTING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 43 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR BIOANALYTICAL TESTING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 133
TABLE 44 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR BIOANALYTICAL TESTING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 133
TABLE 45 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOANALYTICAL TESTING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 46 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR BIOANALYTICAL TESTING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 47 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR BIOANALYTICAL TESTING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 48 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS 135
TABLE 49 CLINICAL TRIAL SERVICES MARKET FOR CLINICAL TRIAL DATA MANAGEMENT SERVICES, BY TYPE, 2024–2031 (USD MILLION) 136
TABLE 50 CLINICAL TRIAL SERVICES MARKET FOR CLINICAL TRIAL DATA MANAGEMENT SERVICES, BY REGION, 2024–2031 (USD MILLION) 137
TABLE 51 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR CLINICAL TRIAL DATA MANAGEMENT SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 52 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR CLINICAL TRIAL DATA MANAGEMENT SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 53 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR CLINICAL TRIAL DATA MANAGEMENT SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 54 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR CLINICAL TRIAL DATA MANAGEMENT SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 55 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR CLINICAL TRIAL DATA MANAGEMENT SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 56 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR CLINICAL TRIAL DATA MANAGEMENT SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 57 CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS, BY REGION,
2024–2031 (USD MILLION) 140
TABLE 58 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 59 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 60 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 61 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 62 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 63 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR BIOSTATISTICS,
BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 64 CLINICAL TRIAL SERVICES MARKET FOR OTHER DATA MANAGEMENT SERVICES,
BY REGION, 2024–2031 (USD MILLION) 143
TABLE 65 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OTHER DATA MANAGEMENT SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 66 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR OTHER DATA MANAGEMENT SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 67 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR OTHER DATA MANAGEMENT SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 68 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OTHER DATA MANAGEMENT SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 69 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR OTHER DATA MANAGEMENT SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 70 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR OTHER DATA MANAGEMENT SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 71 CLINICAL TRIAL SERVICES MARKET FOR CLINICAL TRIAL SUPPLY & LOGISTICS SERVICES, BY REGION, 2024–2031 (USD MILLION) 147
TABLE 72 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR CLINICAL TRIAL SUPPLY & LOGISTICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 73 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR CLINICAL TRIAL SUPPLY & LOGISTICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 74 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR CLINICAL TRIAL SUPPLY & LOGISTICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 75 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR CLINICAL TRIAL SUPPLY & LOGISTICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 149
TABLE 76 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR CLINICAL TRIAL SUPPLY & LOGISTICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 149
TABLE 77 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR CLINICAL TRIAL SUPPLY & LOGISTICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 149
TABLE 78 CLINICAL TRIAL SERVICES MARKET FOR CONSULTING, BY REGION,
2024–2031 (USD MILLION) 150
TABLE 79 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR CONSULTING,
BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 80 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR CONSULTING, BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 81 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR CONSULTING, BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 82 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR CONSULTING,
BY COUNTRY, 2024–2031 (USD MILLION) 152
TABLE 83 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR CONSULTING,
BY COUNTRY, 2024–2031 (USD MILLION) 152
TABLE 84 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR CONSULTING,
BY COUNTRY, 2024–2031 (USD MILLION) 152
TABLE 85 CLINICAL TRIAL SERVICES MARKET FOR PATIENT RECRUITMENT & RETENTION,
BY REGION, 2024–2031 (USD MILLION) 153
TABLE 86 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PATIENT RECRUITMENT & RETENTION, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 87 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PATIENT RECRUITMENT & RETENTION, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 88 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PATIENT RECRUITMENT & RETENTION, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 89 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PATIENT RECRUITMENT & RETENTION, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 90 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PATIENT RECRUITMENT & RETENTION, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 91 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PATIENT RECRUITMENT & RETENTION, BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 92 CLINICAL TRIAL SERVICES MARKET FOR MEDICAL WRITING, BY REGION,
2024–2031 (USD MILLION) 156
TABLE 93 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL WRITING,
BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 94 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL WRITING,
BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 95 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL WRITING,
BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 96 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL WRITING,
BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 97 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL WRITING,
BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 98 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL WRITING,
BY COUNTRY, 2024–2031 (USD MILLION) 159
TABLE 99 CLINICAL TRIAL SERVICES MARKET FOR SAFETY & PHARMACOVIGILANCE,
BY REGION, 2024–2031 (USD MILLION) 160
TABLE 100 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR SAFETY & PHARMACOVIGILANCE, BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 101 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR SAFETY & PHARMACOVIGILANCE, BY COUNTRY, 2024–2031 (USD MILLION) 161
TABLE 102 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR SAFETY & PHARMACOVIGILANCE, BY COUNTRY, 2024–2031 (USD MILLION) 161
TABLE 103 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR SAFETY & PHARMACOVIGILANCE, BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 104 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR SAFETY & PHARMACOVIGILANCE, BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 105 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR SAFETY & PHARMACOVIGILANCE, BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 106 CLINICAL TRIAL SERVICES MARKET FOR SITE CONTRACTS & PAYMENTS,
BY REGION, 2024–2031 (USD MILLION) 163
TABLE 107 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR SITE CONTRACTS & PAYMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 108 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR SITE CONTRACTS & PAYMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 109 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR SITE CONTRACTS & PAYMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 165
TABLE 110 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR SITE CONTRACTS & PAYMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 165
TABLE 111 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR SITE CONTRACTS & PAYMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 165
TABLE 112 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR SITE CONTRACTS & PAYMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 113 CLINICAL TRIAL SERVICES MARKET FOR OTHER SERVICE TYPES, BY REGION, 2024–2031 (USD MILLION) 166
TABLE 114 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OTHER SERVICE TYPES, BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 115 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR OTHER SERVICE TYPES,
BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 116 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR OTHER SERVICE TYPES,
BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 117 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OTHER SERVICE TYPES, BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 118 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR OTHER SERVICE TYPES,
BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 119 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR OTHER SERVICE TYPES, BY COUNTRY, 2024–2031 (USD MILLION) 169
TABLE 120 CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2024–2031 (USD MILLION) 171
TABLE 121 CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY REGION,
2024–2031 (USD MILLION) 172
TABLE 122 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 123 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY,
2024–2031 (USD MILLION) 173
TABLE 124 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 125 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 126 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 127 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PHASE III, BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 128 CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY REGION,
2024–2031 (USD MILLION) 176
TABLE 129 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 130 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY,
2024–2031 (USD MILLION) 177
TABLE 131 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 132 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 133 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 134 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PHASE II, BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 135 CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY REGION,
2024–2031 (USD MILLION) 179
TABLE 136 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 137 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY,
2024–2031 (USD MILLION) 180
TABLE 138 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 139 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 140 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 141 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PHASE I, BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 142 CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY REGION,
2024–2031 (USD MILLION) 182
TABLE 143 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 144 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY,
2024–2031 (USD MILLION) 183
TABLE 145 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 146 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 147 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 148 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 149 CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 186
TABLE 150 CLINICAL TRIAL SERVICES MARKET FOR FULL-SERVICE OUTSOURCING (FSO) MODEL, BY REGION, 2024–2031 (USD MILLION) 187
TABLE 151 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR FULL-SERVICE OUTSOURCING (FSO) MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 152 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR FULL-SERVICE OUTSOURCING (FSO) MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 153 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR FULL-SERVICE OUTSOURCING (FSO) MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 188
TABLE 154 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR FULL-SERVICE OUTSOURCING (FSO) MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 188
TABLE 155 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR FULL-SERVICE OUTSOURCING (FSO) MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 188
TABLE 156 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR FULL-SERVICE OUTSOURCING (FSO) MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 157 CLINICAL TRIAL SERVICES MARKET FOR FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY REGION, 2024–2031 (USD MILLION) 190
TABLE 158 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 159 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 160 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 161 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 162 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 163 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 164 CLINICAL TRIAL SERVICES MARKET FOR HYBRID MODEL, BY REGION,
2024–2031 (USD MILLION) 192
TABLE 165 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR HYBRID MODEL,
BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 166 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 167 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR HYBRID MODEL,
BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 168 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR HYBRID MODEL,
BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 169 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR HYBRID MODEL,
BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 170 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR HYBRID MODEL,
BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 171 CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 196
TABLE 172 CLINICAL TRIAL SERVICES MARKET FOR INTERVENTIONAL STUDY DESIGN,
BY REGION, 2024–2031 (USD MILLION) 197
TABLE 173 CLINICAL TRIAL SERVICES MARKET FOR INTERVENTIONAL STUDY DESIGN FOR NORTH AMERICA, BY COUNTRY, 2024–2031 (USD MILLION) 197
TABLE 174 CLINICAL TRIAL SERVICES MARKET FOR INTERVENTIONAL STUDY DESIGN FOR EUROPE, BY COUNTRY, 2024–2031 (USD MILLION) 198
TABLE 175 CLINICAL TRIAL SERVICES MARKET FOR INTERVENTIONAL STUDY DESIGN FOR ASIA PACIFIC, BY COUNTRY, 2024–2031 (USD MILLION) 198
TABLE 176 CLINICAL TRIAL SERVICES MARKET FOR INTERVENTIONAL STUDY DESIGN FOR LATIN AMERICA, BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 177 CLINICAL TRIAL SERVICES MARKET FOR INTERVENTIONAL STUDY DESIGN FOR MIDDLE EAST, BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 178 CLINICAL TRIAL SERVICES MARKET FOR INTERVENTIONAL STUDY DESIGN FOR GCC COUNTRIES, BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 179 CLINICAL TRIAL SERVICES MARKET FOR OBSERVATIONAL STUDY DESIGN,
BY REGION, 2024–2031 (USD MILLION) 200
TABLE 180 CLINICAL TRIAL SERVICES MARKET FOR OBSERVATIONAL STUDY DESIGN FOR NORTH AMERICA, BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 181 CLINICAL TRIAL SERVICES MARKET FOR OBSERVATIONAL STUDY DESIGN FOR EUROPE, BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 182 CLINICAL TRIAL SERVICES MARKET FOR OBSERVATIONAL STUDY DESIGN FOR
ASIA PACIFIC, BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 183 CLINICAL TRIAL SERVICES MARKET FOR OBSERVATIONAL STUDY DESIGN FOR LATIN AMERICA, BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 184 CLINICAL TRIAL SERVICES MARKET FOR OBSERVATIONAL STUDY DESIGN FOR MIDDLE EAST, BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 185 CLINICAL TRIAL SERVICES MARKET FOR OBSERVATIONAL STUDY DESIGN FOR
GCC COUNTRIES, BY COUNTRY, 2024–2031 (USD MILLION) 203
TABLE 186 CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 205
TABLE 187 NUMBER OF NEW CANCER CASES, BY TYPE, 2022 VS. 2040 206
TABLE 188 CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 208
TABLE 189 CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY REGION,
2024–2031 (USD MILLION) 208
TABLE 190 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 191 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 192 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 193 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 194 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 195 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 196 CLINICAL TRIAL SERVICES MARKET FOR BREAST CANCER, BY REGION,
2024–2031 (USD MILLION) 212
TABLE 197 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BREAST CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 198 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 213
TABLE 199 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR BREAST CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 213
TABLE 200 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BREAST CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 201 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR BREAST CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 202 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR BREAST CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 203 CLINICAL TRIAL SERVICES MARKET FOR LUNG CANCER, BY REGION,
2024–2031 (USD MILLION) 215
TABLE 204 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR LUNG CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 205 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 206 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR LUNG CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 217
TABLE 207 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR LUNG CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 217
TABLE 208 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR LUNG CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 217
TABLE 209 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR LUNG CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 218
TABLE 210 CLINICAL TRIAL SERVICES MARKET FOR COLORECTAL CANCER, BY REGION,
2024–2031 (USD MILLION) 219
TABLE 211 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 219
TABLE 212 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR COLORECTAL CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 220
TABLE 213 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR COLORECTAL CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 220
TABLE 214 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR COLORECTAL CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 215 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR COLORECTAL CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 216 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 217 CLINICAL TRIAL SERVICES MARKET FOR PROSTATE CANCER, BY REGION,
2024–2031 (USD MILLION) 222
TABLE 218 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PROSTATE CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 219 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PROSTATE CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 223
TABLE 220 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PROSTATE CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 223
TABLE 221 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PROSTATE CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 222 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PROSTATE CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 223 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PROSTATE CANCER ,
BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 224 CLINICAL TRIAL SERVICES MARKET FOR OTHER CANCER, BY REGION,
2024–2031 (USD MILLION) 225
TABLE 225 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OTHER CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 226 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR OTHER CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 226
TABLE 227 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR OTHER CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 226
TABLE 228 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OTHER CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 227
TABLE 229 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR OTHER CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 227
TABLE 230 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR OTHER CANCER,
BY COUNTRY, 2024–2031 (USD MILLION) 227
TABLE 231 CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY, BY REGION,
2024–2031 (USD MILLION) 229
TABLE 232 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 229
TABLE 233 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 230
TABLE 234 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 230
TABLE 235 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 236 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 237 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR NEUROLOGY ,
BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 238 CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2024–2031 (USD MILLION) 233
TABLE 239 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 233
TABLE 240 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS,
BY COUNTRY, 2024–2031 (USD MILLION) 234
TABLE 241 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 234
TABLE 242 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 235
TABLE 243 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 235
TABLE 244 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 235
TABLE 245 CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2024–2031 (USD MILLION) 237
TABLE 246 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 237
TABLE 247 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 238
TABLE 248 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 238
TABLE 249 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 250 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 251 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 252 CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2024–2031 (USD MILLION) 240
TABLE 253 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 241
TABLE 254 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 241
TABLE 255 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 256 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 257 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 258 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 243
TABLE 259 CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY, BY REGION,
2024–2031 (USD MILLION) 244
TABLE 260 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 244
TABLE 261 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 245
TABLE 262 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 245
TABLE 263 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 246
TABLE 264 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 246
TABLE 265 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR DERMATOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 246
TABLE 266 CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES,
BY REGION, 2024–2031 (USD MILLION) 247
TABLE 267 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 248
TABLE 268 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 248
TABLE 269 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 249
TABLE 270 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 249
TABLE 271 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 249
TABLE 272 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 250
TABLE 273 CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION) 251
TABLE 274 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 251
TABLE 275 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 252
TABLE 276 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 252
TABLE 277 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 253
TABLE 278 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 253
TABLE 279 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 253
TABLE 280 CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 254
TABLE 281 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 255
TABLE 282 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 255
TABLE 283 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 256
TABLE 284 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 256
TABLE 285 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2024–2031 (USD MILLION) 256
TABLE 286 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 257
TABLE 287 CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY, BY REGION,
2024–2031 (USD MILLION) 258
TABLE 288 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY,
BY COUNTRY, 2024–2031 (USD MILLION) 258
TABLE 289 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2024–2031 (USD MILLION) 259
TABLE 290 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2024–2031 (USD MILLION) 259
TABLE 291 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY,
BY COUNTRY, 2024–2031 (USD MILLION) 260
TABLE 292 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2024–2031 (USD MILLION) 260
TABLE 293 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PSYCHIATRY,
BY COUNTRY, 2024–2031 (USD MILLION) 261
TABLE 294 CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION,
2024–2031 (USD MILLION) 262
TABLE 295 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 262
TABLE 296 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 263
TABLE 297 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 263
TABLE 298 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 264
TABLE 299 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 264
TABLE 300 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR OPHTHALMOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 264
TABLE 301 CLINICAL TRIAL SERVICES MARKET FOR HEMATOLOGY, BY REGION,
2024–2031 (USD MILLION) 265
TABLE 302 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR HEMATOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 266
TABLE 303 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 266
TABLE 304 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR HEMATOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 267
TABLE 305 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR HEMATOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 267
TABLE 306 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR HEMATOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 267
TABLE 307 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR HEMATOLOGY,
BY COUNTRY, 2024–2031 (USD MILLION) 268
TABLE 308 CLINICAL TRIAL SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH,
BY REGION, 2024–2031 (USD MILLION) 269
TABLE 309 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2024–2031 (USD MILLION) 269
TABLE 310 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2024–2031 (USD MILLION) 270
TABLE 311 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2024–2031 (USD MILLION) 270
TABLE 312 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2024–2031 (USD MILLION) 271
TABLE 313 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2024–2031 (USD MILLION) 271
TABLE 314 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2024–2031 (USD MILLION) 271
TABLE 315 CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2024–2031 (USD MILLION) 272
TABLE 316 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 273
TABLE 317 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC AREAS,
BY COUNTRY, 2024–2031 (USD MILLION) 273
TABLE 318 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 274
TABLE 319 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 274
TABLE 320 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 274
TABLE 321 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 275
TABLE 322 CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 277
TABLE 323 CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES, BY REGION,
2024–2031 (USD MILLION) 278
TABLE 324 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES,
BY COUNTRY, 2024–2031 (USD MILLION) 278
TABLE 325 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES,
BY COUNTRY, 2024–2031 (USD MILLION) 278
TABLE 326 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES,
BY COUNTRY, 2024–2031 (USD MILLION) 279
TABLE 327 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES,
BY COUNTRY, 2024–2031 (USD MILLION) 279
TABLE 328 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES,
BY COUNTRY, 2024–2031 (USD MILLION) 279
TABLE 329 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR SMALL MOLECULES,
BY COUNTRY, 2024–2031 (USD MILLION) 280
TABLE 330 CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 280
TABLE 331 CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY REGION,
2024–2031 (USD MILLION) 281
TABLE 332 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS,
BY COUNTRY, 2024–2031 (USD MILLION) 281
TABLE 333 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION) 281
TABLE 334 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION) 282
TABLE 335 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION) 282
TABLE 336 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2024–2031 (USD MILLION) 282
TABLE 337 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS,
BY COUNTRY, 2024–2031 (USD MILLION) 283
TABLE 338 CLINICAL TRIAL SERVICES MARKET FOR MONOCLONAL ANTIBODY, BY REGION, 2024–2031 (USD MILLION) 283
TABLE 339 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR MONOCLONAL ANTIBODY, BY COUNTRY, 2024–2031 (USD MILLION) 284
TABLE 340 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR MONOCLONAL ANTIBODY,
BY COUNTRY, 2024–2031 (USD MILLION) 284
TABLE 341 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR MONOCLONAL ANTIBODY, BY COUNTRY, 2024–2031 (USD MILLION) 284
TABLE 342 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR MONOCLONAL ANTIBODY, BY COUNTRY, 2024–2031 (USD MILLION) 285
TABLE 343 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR MONOCLONAL ANTIBODY, BY COUNTRY, 2024–2031 (USD MILLION) 285
TABLE 344 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR MONOCLONAL ANTIBODY, BY COUNTRY, 2024–2031 (USD MILLION) 285
TABLE 345 CLINICAL TRIAL SERVICES MARKET FOR CELL & GENE THERAPY, BY REGION, 2024–2031 (USD MILLION) 286
TABLE 346 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION) 287
TABLE 347 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR CELL & GENE THERAPY,
BY COUNTRY, 2024–2031 (USD MILLION) 287
TABLE 348 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR CELL & GENE THERAPY,
BY COUNTRY, 2024–2031 (USD MILLION) 287
TABLE 349 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION) 288
TABLE 350 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR CELL & GENE THERAPY,
BY COUNTRY, 2024–2031 (USD MILLION) 288
TABLE 351 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION) 288
TABLE 352 CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS,
BY REGION, 2024–2031 (USD MILLION) 289
TABLE 353 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 289
TABLE 354 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 290
TABLE 355 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 290
TABLE 356 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 291
TABLE 357 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 291
TABLE 358 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR OTHER THERAPEUTIC PRODUCTS, BY COUNTRY, 2024–2031 (USD MILLION) 291
TABLE 359 CLINICAL TRIAL SERVICES MARKET FOR BIOSIMILARS, BY REGION,
2024–2031 (USD MILLION) 292
TABLE 360 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOSIMILARS,
BY COUNTRY, 2024–2031 (USD MILLION) 292
TABLE 361 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 293
TABLE 362 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2031 (USD MILLION) 293
TABLE 363 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOSIMILARS,
BY COUNTRY, 2024–2031 (USD MILLION) 293
TABLE 364 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR BIOSIMILARS,
BY COUNTRY, 2024–2031 (USD MILLION) 294
TABLE 365 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR BIOSIMILARS,
BY COUNTRY, 2024–2031 (USD MILLION) 294
TABLE 366 CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD, BY REGION, 2024–2031 (USD MILLION) 295
TABLE 367 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD, BY COUNTRY, 2024–2031 (USD MILLION) 295
TABLE 368 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD,
BY COUNTRY, 2024–2031 (USD MILLION) 295
TABLE 369 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD,
BY COUNTRY, 2024–2031 (USD MILLION) 296
TABLE 370 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD, BY COUNTRY, 2024–2031 (USD MILLION) 296
TABLE 371 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD, BY COUNTRY, 2024–2031 (USD MILLION) 296
TABLE 372 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICES & IVD, BY COUNTRY, 2024–2031 (USD MILLION) 297
TABLE 373 CLINICAL TRIAL SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 299
TABLE 374 CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION) 300
TABLE 375 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 300
TABLE 376 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 301
TABLE 377 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 301
TABLE 378 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 302
TABLE 379 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 302
TABLE 380 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 302
TABLE 381 CLINICAL TRIAL SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION) 303
TABLE 382 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 303
TABLE 383 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 304
TABLE 384 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 304
TABLE 385 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 305
TABLE 386 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 305
TABLE 387 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 305
TABLE 388 CLINICAL TRIAL SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION) 306
TABLE 389 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 307
TABLE 390 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 307
TABLE 391 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 308
TABLE 392 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 308
TABLE 393 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 309
TABLE 394 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 309
TABLE 395 CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICE COMPANIES,
BY REGION, 2024–2031 (USD MILLION) 310
TABLE 396 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 310
TABLE 397 MEDICAL DEVICE COMPANIES: CLINICAL TRIAL SERVICES MARKET FOR EUROPE, BY COUNTRY, 2024–2031 (USD MILLION) 311
TABLE 398 MEDICAL DEVICE COMPANIES: CLINICAL TRIAL SERVICES MARKET FOR
ASIA PACIFIC, BY COUNTRY, 2024–2031 (USD MILLION) 311
TABLE 399 MEDICAL DEVICE COMPANIES: CLINICAL TRIAL SERVICES MARKET FOR
LATIN AMERICA, BY COUNTRY, 2024–2031 (USD MILLION) 312
TABLE 400 MEDICAL DEVICE COMPANIES: CLINICAL TRIAL SERVICES MARKET FOR
MIDDLE EAST, BY COUNTRY, 2024–2031 (USD MILLION) 312
TABLE 401 MEDICAL DEVICE COMPANIES: CLINICAL TRIAL SERVICES MARKET FOR
GCC COUNTRIES, BY COUNTRY, 2024–2031 (USD MILLION) 312
TABLE 402 ACADEMIC INSTITUTES: CLINICAL TRIAL SERVICES MARKET, BY REGION,
2024–2031 (USD MILLION) 313
TABLE 403 ACADEMIC INSTITUTES: CLINICAL TRIAL SERVICES MARKET FOR NORTH AMERICA, BY COUNTRY, 2024–2031 (USD MILLION) 314
TABLE 404 ACADEMIC INSTITUTES: CLINICAL TRIAL SERVICES MARKET FOR EUROPE,
BY COUNTRY, 2024–2031 (USD MILLION) 314
TABLE 405 ACADEMIC INSTITUTES: CLINICAL TRIAL SERVICES MARKET FOR ASIA PACIFIC,
BY COUNTRY, 2024–2031 (USD MILLION) 315
TABLE 406 ACADEMIC INSTITUTES: CLINICAL TRIAL SERVICES MARKET FOR LATIN AMERICA, BY COUNTRY, 2024–2031 (USD MILLION) 315
TABLE 407 ACADEMIC INSTITUTES: CLINICAL TRIAL SERVICES MARKET FOR MIDDLE EAST,
BY COUNTRY, 2024–2031 (USD MILLION) 315
TABLE 408 ACADEMIC INSTITUTES: CLINICAL TRIAL SERVICES MARKET FOR GCC COUNTRIES, BY COUNTRY, 2024–2031 (USD MILLION) 316
TABLE 409 CLINICAL TRIAL SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 318
TABLE 410 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 319
TABLE 411 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 320
TABLE 412 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 320
TABLE 413 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 321
TABLE 414 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY PHASE,
2024–2031 (USD MILLION) 321
TABLE 415 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 322
TABLE 416 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 322
TABLE 417 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 323
TABLE 418 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 323
TABLE 419 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 323
TABLE 420 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 324
TABLE 421 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 324
TABLE 422 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 324
TABLE 423 US: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 326
TABLE 424 US: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 326
TABLE 425 US: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 327
TABLE 426 US: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2024–2031 (USD MILLION) 327
TABLE 427 US: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 328
TABLE 428 US: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 328
TABLE 429 US: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 329
TABLE 430 US: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 329
TABLE 431 US: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 329
TABLE 432 US: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 330
TABLE 433 US: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 330
TABLE 434 US: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 330
TABLE 435 CANADA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 332
TABLE 436 CANADA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 332
TABLE 437 CANADA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 333
TABLE 438 CANADA: CLINICAL TRIAL SERVICES MARKET, BY PHASE,
2024–2031 (USD MILLION) 333
TABLE 439 CANADA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 334
TABLE 440 CANADA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 334
TABLE 441 CANADA: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 335
TABLE 442 CANADA: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 335
TABLE 443 CANADA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 335
TABLE 444 CANADA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 336
TABLE 445 CANADA: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 336
TABLE 446 CANADA: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 336
TABLE 447 EUROPE: CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 337
TABLE 448 EUROPE: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 338
TABLE 449 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 338
TABLE 450 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 339
TABLE 451 EUROPE: CLINICAL TRIAL SERVICES MARKET, BY PHASE,
2024–2031 (USD MILLION) 339
TABLE 452 EUROPE: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 340
TABLE 453 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 340
TABLE 454 EUROPE: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 341
TABLE 455 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 341
TABLE 456 EUROPE: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 341
TABLE 457 EUROPE: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 342
TABLE 458 EUROPE: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 342
TABLE 459 EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 342
TABLE 460 GERMANY: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 344
TABLE 461 GERMANY: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 344
TABLE 462 GERMANY: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 345
TABLE 463 GERMANY: CLINICAL TRIAL SERVICES MARKET, BY PHASE,
2024–2031 (USD MILLION) 345
TABLE 464 GERMANY: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 346
TABLE 465 GERMANY: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 346
TABLE 466 GERMANY: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 347
TABLE 467 GERMANY: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 347
TABLE 468 GERMANY: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 347
TABLE 469 GERMANY: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 348
TABLE 470 GERMANY: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 348
TABLE 471 GERMANY: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 348
TABLE 472 UK: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 350
TABLE 473 UK: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 350
TABLE 474 UK: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 351
TABLE 475 UK: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2024–2031 (USD MILLION) 351
TABLE 476 UK: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 352
TABLE 477 UK: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 352
TABLE 478 UK: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 353
TABLE 479 UK: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 353
TABLE 480 UK: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 353
TABLE 481 UK: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 354
TABLE 482 UK: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 354
TABLE 483 UK: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 354
TABLE 484 FRANCE: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 356
TABLE 485 FRANCE: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 356
TABLE 486 FRANCE: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 357
TABLE 487 FRANCE: CLINICAL TRIAL SERVICES MARKET, BY PHASE,
2024–2031 (USD MILLION) 357
TABLE 488 FRANCE: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 358
TABLE 489 FRANCE: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 358
TABLE 490 FRANCE: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 359
TABLE 491 FRANCE: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 359
TABLE 492 FRANCE: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 359
TABLE 493 FRANCE: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 360
TABLE 494 FRANCE: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 360
TABLE 495 FRANCE: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 360
TABLE 496 ITALY: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 361
TABLE 497 ITALY: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 362
TABLE 498 ITALY: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 362
TABLE 499 ITALY: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2024–2031 (USD MILLION) 362
TABLE 500 ITALY: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 363
TABLE 501 ITALY: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 363
TABLE 502 ITALY: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 364
TABLE 503 ITALY: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 364
TABLE 504 ITALY: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 364
TABLE 505 ITALY: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 365
TABLE 506 ITALY: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 365
TABLE 507 ITALY: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 365
TABLE 508 SPAIN: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 366
TABLE 509 SPAIN: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 367
TABLE 510 SPAIN: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 367
TABLE 511 SPAIN: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2024–2031 (USD MILLION) 367
TABLE 512 SPAIN: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 368
TABLE 513 SPAIN: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 368
TABLE 514 SPAIN: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 369
TABLE 515 SPAIN: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 369
TABLE 516 SPAIN: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 369
TABLE 517 SPAIN: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 370
TABLE 518 SPAIN: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 370
TABLE 519 SPAIN: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 370
TABLE 520 REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 372
TABLE 521 REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 372
TABLE 522 REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 373
TABLE 523 REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET, BY PHASE,
2024–2031 (USD MILLION) 373
TABLE 524 REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 374
TABLE 525 REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 374
TABLE 526 REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 375
TABLE 527 REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 375
TABLE 528 REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 375
TABLE 529 REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 376
TABLE 530 REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 376
TABLE 531 REST OF EUROPE: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 376
TABLE 532 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 378
TABLE 533 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 378
TABLE 534 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 379
TABLE 535 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 379
TABLE 536 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY PHASE,
2024–2031 (USD MILLION) 379
TABLE 537 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 380
TABLE 538 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 380
TABLE 539 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 381
TABLE 540 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 381
TABLE 541 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 381
TABLE 542 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 382
TABLE 543 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 382
TABLE 544 ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 382
TABLE 545 CHINA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 384
TABLE 546 CHINA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 384
TABLE 547 CHINA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 385
TABLE 548 CHINA: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2024–2031 (USD MILLION) 385
TABLE 549 CHINA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 386
TABLE 550 CHINA: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 386
TABLE 551 CHINA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 387
TABLE 552 CHINA: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 387
TABLE 553 CHINA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 387
TABLE 554 CHINA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 388
TABLE 555 CHINA: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 388
TABLE 556 CHINA: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 388
TABLE 557 INDIA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 390
TABLE 558 INDIA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 390
TABLE 559 INDIA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 391
TABLE 560 INDIA: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2024–2031 (USD MILLION) 391
TABLE 561 INDIA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 392
TABLE 562 INDIA: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 392
TABLE 563 INDIA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 393
TABLE 564 INDIA: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 393
TABLE 565 INDIA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 393
TABLE 566 INDIA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 394
TABLE 567 INDIA: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 394
TABLE 568 INDIA: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 394
TABLE 569 JAPAN: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 395
TABLE 570 JAPAN: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 396
TABLE 571 JAPAN: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 396
TABLE 572 JAPAN: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2024–2031 (USD MILLION) 396
TABLE 573 JAPAN: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 397
TABLE 574 JAPAN: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 397
TABLE 575 JAPAN: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 398
TABLE 576 JAPAN: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 398
TABLE 577 JAPAN: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 398
TABLE 578 JAPAN: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 399
TABLE 579 JAPAN: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 399
TABLE 580 JAPAN: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 399
TABLE 581 AUSTRALIA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 400
TABLE 582 AUSTRALIA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 401
TABLE 583 AUSTRALIA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 401
TABLE 584 AUSTRALIA: CLINICAL TRIAL SERVICES MARKET, BY PHASE,
2024–2031 (USD MILLION) 401
TABLE 585 AUSTRALIA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 402
TABLE 586 AUSTRALIA: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 402
TABLE 587 AUSTRALIA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 403
TABLE 588 AUSTRALIA: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 403
TABLE 589 AUSTRALIA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 403
TABLE 590 AUSTRALIA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 404
TABLE 591 AUSTRALIA: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 404
TABLE 592 AUSTRALIA: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 404
TABLE 593 SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 406
TABLE 594 SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 406
TABLE 595 SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 407
TABLE 596 SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET, BY PHASE,
2024–2031 (USD MILLION) 407
TABLE 597 SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 408
TABLE 598 SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 408
TABLE 599 SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 409
TABLE 600 SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 409
TABLE 601 SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 409
TABLE 602 SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 410
TABLE 603 SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 410
TABLE 604 SOUTH KOREA: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 410
TABLE 605 REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 411
TABLE 606 REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 412
TABLE 607 REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 412
TABLE 608 REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY PHASE,
2024–2031 (USD MILLION) 412
TABLE 609 REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 413
TABLE 610 REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 413
TABLE 611 REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 414
TABLE 612 REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS,
BY TYPE, 2024–2031 (USD MILLION) 414
TABLE 613 REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 414
TABLE 614 REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2024–2031 (USD MILLION) 415
TABLE 615 REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 415
TABLE 616 REST OF ASIA PACIFIC: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 415
TABLE 617 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 416
TABLE 618 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 416
TABLE 619 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 417
TABLE 620 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY PHASE,
2024–2031 (USD MILLION) 417
TABLE 621 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 418
TABLE 622 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 418
TABLE 623 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 419
TABLE 624 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 419
TABLE 625 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 419
TABLE 626 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 420
TABLE 627 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 420
TABLE 628 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 420
TABLE 629 LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 421
TABLE 630 BRAZIL: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 422
TABLE 631 BRAZIL: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 422
TABLE 632 BRAZIL: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 423
TABLE 633 BRAZIL: CLINICAL TRIAL SERVICES MARKET, BY PHASE,
2024–2031 (USD MILLION) 423
TABLE 634 BRAZIL: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 424
TABLE 635 BRAZIL: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 424
TABLE 636 BRAZIL: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 425
TABLE 637 BRAZIL: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 425
TABLE 638 BRAZIL: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 425
TABLE 639 BRAZIL: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 426
TABLE 640 BRAZIL: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 426
TABLE 641 BRAZIL: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 426
TABLE 642 MEXICO: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 427
TABLE 643 MEXICO: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 428
TABLE 644 MEXICO: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 428
TABLE 645 MEXICO: CLINICAL TRIAL SERVICES MARKET, BY PHASE,
2024–2031 (USD MILLION) 428
TABLE 646 MEXICO: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 429
TABLE 647 MEXICO: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 429
TABLE 648 MEXICO: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 430
TABLE 649 MEXICO: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 430
TABLE 650 MEXICO: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 430
TABLE 651 MEXICO: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 431
TABLE 652 MEXICO: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 431
TABLE 653 MEXICO: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 431
TABLE 654 REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 432
TABLE 655 REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 432
TABLE 656 REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 433
TABLE 657 REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY PHASE,
2024–2031 (USD MILLION) 433
TABLE 658 REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET,
BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 434
TABLE 659 REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 434
TABLE 660 REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 435
TABLE 661 REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS,
BY TYPE, 2024–2031 (USD MILLION) 435
TABLE 662 REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET,
BY DELIVERY MODEL, 2024–2031 (USD MILLION) 435
TABLE 663 REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2024–2031 (USD MILLION) 436
TABLE 664 REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION) 436
TABLE 665 REST OF LATIN AMERICA: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE,
2024–2031 (USD MILLION) 436
TABLE 666 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 437
TABLE 667 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 437
TABLE 668 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 438
TABLE 669 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY PHASE,
2024–2031 (USD MILLION) 438
TABLE 670 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 439
TABLE 671 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 439
TABLE 672 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 440
TABLE 673 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 440
TABLE 674 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 440
TABLE 675 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 441
TABLE 676 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 441
TABLE 677 MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 441
TABLE 678 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 442
TABLE 679 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 442
TABLE 680 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 443
TABLE 681 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 443
TABLE 682 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY PHASE,
2024–2031 (USD MILLION) 443
TABLE 683 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 444
TABLE 684 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 444
TABLE 685 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 445
TABLE 686 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 445
TABLE 687 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 445
TABLE 688 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 446
TABLE 689 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 446
TABLE 690 GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 446
TABLE 691 SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 447
TABLE 692 SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 448
TABLE 693 SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 448
TABLE 694 SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET, BY PHASE,
2024–2031 (USD MILLION) 448
TABLE 695 SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 449
TABLE 696 SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024–2031 (USD MILLION) 449
TABLE 697 SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 450
TABLE 698 SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024–2031 (USD MILLION) 450
TABLE 699 SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 450
TABLE 700 SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 451
TABLE 701 SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 451
TABLE 702 SAUDI ARABIA: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 451
TABLE 703 UAE: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 452
TABLE 704 UAE: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 453
TABLE 705 UAE: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 453
TABLE 706 UAE: CLINICAL TRIAL SERVICES MARKET, BY PHASE, 2024–2031 (USD MILLION) 453
TABLE 707 UAE: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 454
TABLE 708 UAE: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 454
TABLE 709 UAE: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 455
TABLE 710 UAE: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 455
TABLE 711 UAE: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 455
TABLE 712 UAE: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 456
TABLE 713 UAE: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 456
TABLE 714 UAE: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 456
TABLE 715 REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 457
TABLE 716 REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 457
TABLE 717 REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 458
TABLE 718 REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY PHASE,
2024–2031 (USD MILLION) 458
TABLE 719 REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET,
BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 459
TABLE 720 REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 459
TABLE 721 REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET, BY MODALITY, 2024–2031 (USD MILLION) 460
TABLE 722 REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS,
BY TYPE, 2024–2031 (USD MILLION) 460
TABLE 723 REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET,
BY DELIVERY MODEL, 2024–2031 (USD MILLION) 460
TABLE 724 REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET,
BY STUDY DESIGN, 2024–2031 (USD MILLION) 461
TABLE 725 REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET,
BY END USER, 2024–2031 (USD MILLION) 461
TABLE 726 REST OF GCC COUNTRIES: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE,
2024–2031 (USD MILLION) 461
TABLE 727 REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE, 2024–2031 (USD MILLION) 462
TABLE 728 REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 462
TABLE 729 REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 463
TABLE 730 REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY PHASE,
2024–2031 (USD MILLION) 463
TABLE 731 REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET,
BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 464
TABLE 732 REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY,
BY TYPE, 2024–2031 (USD MILLION) 464
TABLE 733 REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 465
TABLE 734 REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS,
BY TYPE, 2024–2031 (USD MILLION) 465
TABLE 735 REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL, 2024–2031 (USD MILLION) 465
TABLE 736 REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN, 2024–2031 (USD MILLION) 466
TABLE 737 REST OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 466
TABLE 738 RETS OF MIDDLE EAST: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 466
TABLE 739 AFRICA: CLINICAL TRIAL SERVICES MARKET, BY SERVICE TYPE,
2024–2031 (USD MILLION) 467
TABLE 740 AFRICA: CLINICAL TRIAL SERVICES MARKET FOR LABORATORY SERVICES,
BY SERVICE TYPE, 2024–2031 (USD MILLION) 468
TABLE 741 AFRICA: CLINICAL TRIAL SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY SERVICE TYPE, 2024–2031 (USD MILLION) 468
TABLE 742 AFRICA: CLINICAL TRIAL SERVICES MARKET, BY PHASE,
2024–2031 (USD MILLION) 468
TABLE 743 AFRICA: CLINICAL TRIAL SERVICES MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 469
TABLE 744 AFRICA: CLINICAL TRIAL SERVICES MARKET FOR ONCOLOGY, BY TYPE,
2024–2031 (USD MILLION) 469
TABLE 745 AFRICA: CLINICAL TRIAL SERVICES MARKET, BY MODALITY,
2024–2031 (USD MILLION) 470
TABLE 746 AFRICA: CLINICAL TRIAL SERVICES MARKET FOR BIOLOGICS, BY TYPE,
2024–2031 (USD MILLION) 470
TABLE 747 AFRICA: CLINICAL TRIAL SERVICES MARKET, BY DELIVERY MODEL,
2024–2031 (USD MILLION) 470
TABLE 748 AFRICA: CLINICAL TRIAL SERVICES MARKET, BY STUDY DESIGN,
2024–2031 (USD MILLION) 471
TABLE 749 AFRICA: CLINICAL TRIAL SERVICES MARKET, BY END USER,
2024–2031 (USD MILLION) 471
TABLE 750 AFRICA: CLINICAL TRIAL SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024–2031 (USD MILLION) 471
TABLE 751 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CLINICAL TRIAL SERVICES MARKET, JANUARY 2023–JULY 2026 473
TABLE 752 CLINICAL TRIAL SERVICES MARKET: DEGREE OF COMPETITION 477
TABLE 753 CLINICAL TRIAL SERVICES MARKET: REGION FOOTPRINT 482
TABLE 754 CLINICAL TRIAL SERVICES MARKET: SERVICE TYPE FOOTPRINT 483
TABLE 755 CLINICAL TRIAL SERVICES MARKET: PHASE FOOTPRINT 484
TABLE 756 CLINICAL TRIAL SERVICES MARKET: DETAILED LIST OF KEY STARTUP/SMES 487
TABLE 757 CLINICAL TRIAL SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 488
TABLE 758 CLINICAL TRIAL SERVICES MARKET: SERVICE LAUNCHES,
JANUARY 2023–JULY 2026 491
TABLE 759 CLINICAL TRIAL SERVICES MARKET: DEALS, JANUARY 2023–JULY 2026 492
TABLE 760 CLINICAL TRIAL SERVICES MARKET: EXPANSIONS, JANUARY 2023–JULY 2026 493
TABLE 761 IQVIA INC.: COMPANY OVERVIEW 494
TABLE 762 IQVIA INC.: SOLUTIONS/SERVICES OFFERED 495
TABLE 763 IQVIA INC.: SERVICE/ SOLUTION LAUNCHES, JANUARY 2023–JULY 2026 497
TABLE 764 IQVIA INC.: DEALS, JANUARY 2023–JULY 2026 498
TABLE 765 ICON PLC: COMPANY OVERVIEW 501
TABLE 766 ICON PLC.: SERVICES/SOLUTIONS OFFERED 502
TABLE 767 ICON PLC.: SERVICE LAUNCHES, JANUARY 2023–JULY 2026 504
TABLE 768 ICON PLC: DEALS, JANUARY 2023–JULY 2026 505
TABLE 769 ICON PLC.: EXPANSIONS, JANUARY 2023–JULY 2026 506
TABLE 770 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 507
TABLE 771 THERMO FISHER SCIENTIFIC INC.: SERVICES/SOLUTIONS OFFERED 508
TABLE 772 THERMO FISHER SCIENTIFIC, INC.: SERVICE LAUNCHES,
JANUARY 2023–JULY 2026 511
TABLE 773 THERMO FISHER SCIENTIFIC, INC.: DEALS, JANUARY 2021–APRIL 2026 512
TABLE 774 THERMO FISHER SCIENTIFIC, INC.: EXPANSIONS, JANUARY 2023–JULY 2026 513
TABLE 775 FORTREA: COMPANY OVERVIEW 515
TABLE 776 FORTREA, INC.: SERVICES/SOLUTIONS OFFERED 516
TABLE 777 FORTREA, INC.: SERVICE LAUNCHES, JANUARY 2023–JULY 2026 519
TABLE 778 FORTREA, INC.: DEALS, JANUARY 2023–JULY 2026 520
TABLE 779 FORTREA, INC.: EXPANSIONS, JANUARY 2023–JULY 2026 520
TABLE 780 FORTREA, INC.: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 520
TABLE 781 SYNEOS HEALTH: COMPANY OVERVIEW 522
TABLE 782 SYNEOS HEALTH: SERVICES/SOLUTIONS OFFERED 523
TABLE 783 SYNEOS HEALTH: SERVICE LAUNCHES, JANUARY 2023–JULY 2026 524
TABLE 784 SYNEOS HEALTH: DEALS, JANUARY 2023–JULY 2026 525
TABLE 785 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW 526
TABLE 786 LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICES/
SOLUTIONS OFFERED 527
TABLE 787 LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICE LAUNCHES, JANUARY 2023–JULY 2026 528
TABLE 788 LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS,
JANUARY 2023–JULY 2026 529
TABLE 789 LABORATORY CORPORATION OF AMERICA HOLDINGS: EXPANSIONS,
JANUARY 2023–JULY 2026 530
TABLE 790 MEDPACE: COMPANY OVERVIEW 531
TABLE 791 MEDPACE: SERVICES/SOLUTIONS OFFERED 532
TABLE 792 WUXI APPTEC: COMPANY OVERVIEW 534
TABLE 793 WUXI APPTEC: SERVICES/SOLUTIONS OFFERED 535
TABLE 794 WUXI APPTEC: DEALS, JANUARY 2023–JULY 2026 537
TABLE 795 WUXI APPTEC: EXPANSIONS, JANUARY 2023–JULY 2026 537
TABLE 796 WUXI APPTEC: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 537
TABLE 797 FRONTAGE LABS: COMPANY OVERVIEW 538
TABLE 798 FRONTAGE LABS: SERVICES/SOLUTIONS OFFERED 539
TABLE 799 FRONTAGE LABS: DEALS, JANUARY 2023–JULY 2026 540
TABLE 800 PHARMARON: COMPANY OVERVIEW 541
TABLE 801 PHARMARON: SERVICES/SOLUTIONS OFFERED 543
TABLE 802 TIGERMED: COMPANY OVERVIEW 544
TABLE 803 TIGERMED: SERVICES OFFERED 545
TABLE 804 TIGERMED: SERVICE APPROVALS, JANUARY 2023–JULY 2026 547
TABLE 805 TIGERMED: DEALS, JANUARY 2023–JULY 2026 548
TABLE 806 SGS SA: COMPANY OVERVIEW 549
TABLE 807 SGS SA: SERVICES/SOLUTIONS OFFERED 550
TABLE 808 SGS SA: DEALS, JANUARY 2023–JULY 2026 552
TABLE 809 SGS SA: EXPANSIONS, JANUARY 2023–JULY 2026 552
TABLE 810 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 553
TABLE 811 EUROFINS SCIENTIFIC: SERVICES/SOLUTIONS OFFERED 554
TABLE 812 LINICAL: COMPANY OVERVIEW 556
TABLE 813 LINICAL: SERVICES/SOLUTIONS OFFERED 557
TABLE 814 LINICAL: EXPANSIONS, JANUARY 2023–JULY 2026 558
TABLE 815 PAREXEL INTERNATIONAL CORPORATION: COMPANY OVERVIEW 559
TABLE 816 PAREXEL INTERNATIONAL CORPORATION: SERVICES/SOLUTIONS OFFERED 559
TABLE 817 PAREXEL INTERNATIONAL CORPORATION: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026 561
TABLE 818 PAREXEL INTERNATIONAL CORPORATION: DEALS, JANUARY 2023–JULY 2026 561
TABLE 819 PAREXEL INTERNATIONAL CORPORATION: EXPANSIONS,
JANUARY 2021–JANUARY 2025 562
TABLE 820 PSI CRO AG: COMPANY OVERVIEW 563
TABLE 821 PSI CRO AG: SERVICES/SOLUTIONS OFFERED 563
TABLE 822 PSI CRO AG: SERVICE LAUNCHES, JANUARY 2023–JULY 2026 564
TABLE 823 PSI CRO AG: DEALS, JANUARY 2023–JULY 2026 564
TABLE 824 PSI CRO AG: EXPANSIONS, JANUARY 2023–JULY 2026 565
TABLE 825 NOVOTECH: COMPANY OVERVIEW 566
TABLE 826 NOVOTECH: SERVICES/SOLUTIONS OFFERED 566
TABLE 827 NOVOTECH HEALTH HOLDINGS: DEALS, JANUARY 2023–JULY 2026 569
TABLE 828 BIOAGILE: COMPANY OVERVIEW 570
TABLE 829 BIOAGILE: SERVICES/SOLUTIONS OFFERED 570
TABLE 830 ADVANCED CLINICAL: COMPANY OVERVIEW 572
TABLE 831 ADVANCED CLINICAL: SERVICES/SOLUTIONS OFFERED 572
TABLE 832 ADVANCED CLINICAL: DEALS, JANUARY 2023–JULY 2026 573
TABLE 833 FIRMA CLINICAL RESEARCH: COMPANY OVERVIEW 574
TABLE 834 FIRMA CLINICAL RESEARCH: SERVICES/SOLUTIONS OFFERED 574
TABLE 835 WORLDWIDE CLINICAL TRIALS: COMPANY OVERVIEW 575
TABLE 836 PROPHARMA: COMPANY OVERVIEW 576
TABLE 837 ALLUCENT: COMPANY OVERVIEW 578
TABLE 838 PREMIER RESEARCH: COMPANY OVERVIEW 579
TABLE 839 CAIDYA: COMPANY OVERVIEW 580
TABLE 840 ERGOMED GROUP: COMPANY OVERVIEW 581
TABLE 841 CLARIO: COMPANY OVERVIEW 583
TABLE 842 PRECISION MEDICINE GROUP, LLC: COMPANY OVERVIEW 584
TABLE 843 EPS HOLDINGS, INC.: COMPANY OVERVIEW 585
TABLE 844 GUIRES INC. (PEPGRA): COMPANY OVERVIEW 586
TABLE 845 KCR S.A.: COMPANY OVERVIEW 587
TABLE 846 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 596
TABLE 847 CLINICAL TRIAL SERVICES MARKET: RISK ANALYSIS 599
FIGURE 1 CLINICAL TRIAL SERVICES MARKET SEGMENTATION 58
FIGURE 2 MARKET SCENARIO 63
FIGURE 3 GLOBAL CLINICAL TRIAL SERVICES MARKET, 2024–2031 63
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CLINICAL TRIAL SERVICES MARKET, 2023–2025 64
FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF CLINICAL TRIAL SERVICES MARKET 65
FIGURE 6 HIGH-GROWTH SEGMENTS IN CLINICAL TRIAL SERVICES MARKET, 2026–2031 66
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN CLINICAL TRIAL SERVICES MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 67
FIGURE 8 INCREASING SIZE OF CLINICAL DEVELOPMENT PIPELINE TO PROPEL
MARKET GROWTH 69
FIGURE 9 US AND SMALL MOLECULES SEGMENT COMMANDED LARGEST MARKET
SHARES IN 2025 70
FIGURE 10 CHINA TO REGISTER HIGHER CAGR DURING FORECAST PERIOD 71
FIGURE 11 CLINICAL TRIAL SERVICES MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 72
FIGURE 12 ACTIVE PHARMACEUTICAL PIPELINE, 2015–2026 75
FIGURE 13 REVENUE SHIFT AND NEW POCKETS FOR CLINICAL TRIAL SERVICE PROVIDERS 82
FIGURE 14 INDICATIVE PRICING ANALYSIS, BY REGION, 2025 84
FIGURE 15 CLINICAL TRIAL SERVICES MARKET: VALUE CHAIN ANALYSIS 85
FIGURE 16 CLINICAL TRIAL SERVICES MARKET: ECOSYSTEM ANALYSIS 87
FIGURE 17 PORTER’S FIVE FORCES ANALYSIS: CLINICAL TRIAL SERVICES MARKET 90
FIGURE 18 AI USE CASES 102
FIGURE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CLINICAL TRIAL SERVICES, BY MODALITY 113
FIGURE 20 KEY BUYING CRITERIA FOR CLINICAL TRIAL SERVICES ACROSS END USERS 114
FIGURE 21 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2023–2025 171
FIGURE 22 ONCOLOGY TRIALS SHARE OF THE DEVELOPMENT PIPELINE, 2014-2025 207
FIGURE 23 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION) 236
FIGURE 24 NORTH AMERICA: CLINICAL TRIAL SERVICES MARKET SNAPSHOT 319
FIGURE 25 ASIA PACIFIC: CLINICAL TRIALS MARKET SNAPSHOT 377
FIGURE 26 CLINICAL TRIAL SERVICES MARKET: REVENUE ANALYSIS OF KEY PLAYERS,
2023–2025 (USD BILLION) 475
FIGURE 27 CLINICAL TRIAL SERVICES MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025 476
FIGURE 28 CLINICAL TRIAL SERVICES MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2025 480
FIGURE 29 CLINICAL TRIAL SERVICES MARKET: COMPANY FOOTPRINT 481
FIGURE 30 CLINICAL TRIAL SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 486
FIGURE 31 CLINICAL TRIAL SERVICES MARKET: YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2025 489
FIGURE 32 CLINICAL TRIAL SERVICES MARKET: EV/EBITDA OF KEY VENDORS, 2025 489
FIGURE 33 CLINICAL TRIAL SERVICES MARKET: BRAND/SERVICE COMPARISON 490
FIGURE 34 IQVIA INC.: COMPANY SNAPSHOT (2025) 495
FIGURE 35 ICON PLC: COMPANY SNAPSHOT (2025) 502
FIGURE 36 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 508
FIGURE 37 FORTREA: COMPANY SNAPSHOT (2025) 516
FIGURE 38 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2025) 527
FIGURE 39 MEDPACE: COMPANY SNAPSHOT (2025) 532
FIGURE 40 WUXI APPTEC: COMPANY SNAPSHOT (2025) 535
FIGURE 41 FRONTAGE LABS: COMPANY SNAPSHOT (2024) 539
FIGURE 42 PHARMARON: COMPANY SNAPSHOT (2025) 542
FIGURE 43 TIGERMED: COMPANY SNAPSHOT (2025) 545
FIGURE 44 SGS SA: COMPANY SNAPSHOT (2025) 550
FIGURE 45 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025) 554
FIGURE 46 LINICAL: COMPANY SNAPSHOT (2025) 557
FIGURE 47 CLINICAL TRIAL SERVICES MARKET: RESEARCH DESIGN 588
FIGURE 48 CLINICAL TRIAL SERVICES MARKET: BREAKDOWN OF PRIMARIES
(DEMAND- AND SUPPLY-SIDE PARTICIPANTS) 590
FIGURE 49 GLOBAL CLINICAL TRIAL SERVICES MARKET SIZE ESTIMATION
(SUPPLY-SIDE ANALYSIS), 2025 591
FIGURE 50 CLINICAL TRIAL SERVICES MARKET ESTIMATION: APPROACH 1
(COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025 592
FIGURE 51 ILLUSTRATIVE EXAMPLE OF IQVIA INC.: REVENUE SHARE ANALYSIS, 2025 592
FIGURE 52 CLINICAL TRIAL SERVICES MARKET SIZE VALIDATION FROM PRIMARY SOURCES 593
FIGURE 53 TOP-DOWN APPROACH 594
FIGURE 54 GLOBAL CLINICAL TRIAL SERVICES MARKET: CAGR PROJECTIONS, 2026–2031 596
FIGURE 55 CLINICAL TRIAL SERVICES MARKET: DATA TRIANGULATION METHODOLOGY 597
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們